12 February 2019
Visiongain has published a new pharma report Global Biomarkers Market Report: Consumables, Services, Software, Biomarker Discovery, Biomarker Diagnostics, Biomarker Services, Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS Diseases, Autoimmune Diseases.
The use of biomarkers in drug development, including as surrogate endpoints for clinical trials, is rapidly gaining acceptance within the pharmaceutical industry and with regulatory bodies. A great deal of research has been performed in the past decade alone for the discovery of disease biomarkers, identifying new drug targets, as well indicators for treatment response. This field is being driven by increased investment by pharmaceutical companies and academia, as well non-profit organisations.
This report profiled the selected companies: AB SCIEX, Abbott Laboratories, Agilent, AstraZeneca, Axela Inc, Caprion Proteomics, Charles River Laboratories, Critical Diagnostics, Epigenomics and others.
The analyst commented that "The increased demand for diagnostic tests that will identify patients who are most likely to respond to treatment will be a key factor in the growth of this sector. The biomarker discovery sector will also grow strongly, as a result of increased interest in biomarker research within the pharmaceutical industry. Future growth in the genomic biomarkers market will be driven by progress in mapping the genome of specific diseases."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.